Table 1 Predictive molecular pathology of the included patients at baseline (T0) and first disease restaging (T1) undergoing first-line treatments.
ID | Tissue single-gene testing (RT-PCR, IHC) | Treatment | ctDNA T0 (NGS) | MAF T0 (%) | ctDNA T1 (NGS) | MAF T1 (%) | CT SCAN | cfDNA T0 (ng/µl) | cfDNA T1 (ng/µl) |
|---|---|---|---|---|---|---|---|---|---|
LEXO 14 | p.E746_A750del, EGFR | afatinib | p.E746_A750del, EGFR p.T790M, EGFR p.R175H, TP53 | 13.1% 10.3% 2.33% | p.E746_A750del, EGFR; p.T790M, EGFR; p.R175H, TP53 | 0% 89.5% 45.76% | PD | 0.28 | 0.42 |
LEXO 16 | ALK+ | alectinib | p.E746_A750del, EGFR | 1.42% | ND | 0% | PD | 0.23 | 0.43 |
LEXO 27 | ALK+ | alectinib | ND | N.A. | ND | N.A. | PR | 0.47 | 0.34 |
LEXO 33 | p.E746_A750del, EGFR | osimertinib | p.L747_P753delinsS, EGFR | 0.43% | p.L747_P753delinsS, EGFR; p.V600E, BRAF; p.G12D, KRAS | 15.13% 8.8% 2.02% | PD | 0.84 | 0.54 |
LEXO 37 | - | CT + IO | ND | N.A. | p.G12V, KRAS | 7.60% | PD | 0.63 | 4.01 |
LEXO 42 | p.L861Q, EGFR | osimertinib | p.L861Q, EGFR | 0.4% | ND | 0% | PR | 0.59 | 0.38 |
LEXO 44 | - | CT + IO | ND | N.A. | p.M237I, TP53 | 0.21% | PD | 0.37 | 0.78 |
LEXO 51 | p.E746_A750del, EGFR | osimertinib | ND | N.A. | p.G12C, KRAS; p.G245S, TP53 | 5.03% 0.43% | PD | 0.24 | 0.46 |
LEXO 53 | p.L858R, EGFR | osimertinib | p.L858R, EGFR | 1.5% | ND | 0% | PR | 0.92 | 0.46 |
LEXO 54 | p.V600E, BRAF | dabrafenib+ trametinib | p.V600E, BRAF | 2.76% | ND | 0%. | PR | 0.61 | 0.91 |
LEXO 65 | p.L858R, EGFR | osimertinib | p.L858R, EGFR | 0.55% | ND | 0% | PR | 0.45 | 0.57 |
LEXO 70 | ALK+ | alectinib | ND | N.A. | ND | N.A. | PR | 8.07 | 2.74 |
